JP2020528936A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020528936A5 JP2020528936A5 JP2020527850A JP2020527850A JP2020528936A5 JP 2020528936 A5 JP2020528936 A5 JP 2020528936A5 JP 2020527850 A JP2020527850 A JP 2020527850A JP 2020527850 A JP2020527850 A JP 2020527850A JP 2020528936 A5 JP2020528936 A5 JP 2020528936A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fragment
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000012634 fragment Substances 0.000 claims description 255
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 181
- 238000000034 method Methods 0.000 claims description 104
- 206010028980 Neoplasm Diseases 0.000 claims description 66
- 201000011510 cancer Diseases 0.000 claims description 61
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 33
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims description 31
- 102100032257 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims description 31
- 210000004027 cell Anatomy 0.000 claims description 31
- 239000000611 antibody drug conjugate Substances 0.000 claims description 26
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 26
- 150000001413 amino acids Chemical class 0.000 claims description 22
- 108060003951 Immunoglobulin Proteins 0.000 claims description 16
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims description 16
- 229940127089 cytotoxic agent Drugs 0.000 claims description 16
- 239000002254 cytotoxic agent Substances 0.000 claims description 16
- 102000018358 immunoglobulin Human genes 0.000 claims description 16
- 229960001592 paclitaxel Drugs 0.000 claims description 16
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical group O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 16
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims description 14
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 14
- 238000002512 chemotherapy Methods 0.000 claims description 14
- 229960005277 gemcitabine Drugs 0.000 claims description 14
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 8
- 231100000433 cytotoxic Toxicity 0.000 claims description 8
- 230000001472 cytotoxic effect Effects 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 238000011275 oncology therapy Methods 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 239000000562 conjugate Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 4
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 4
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010027476 Metastases Diseases 0.000 claims description 4
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 238000009169 immunotherapy Methods 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- 238000011503 in vivo imaging Methods 0.000 claims description 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101150030213 Lag3 gene Proteins 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000037842 advanced-stage tumor Diseases 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 claims description 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 2
- 210000000170 cell membrane Anatomy 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000037819 metastatic cancer Diseases 0.000 claims description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
- 210000004500 stellate cell Anatomy 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 80
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 description 3
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023069335A JP7629651B2 (ja) | 2017-07-27 | 2023-04-20 | Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用 |
| JP2025011548A JP2025066140A (ja) | 2017-07-27 | 2025-01-27 | Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762537914P | 2017-07-27 | 2017-07-27 | |
| US62/537,914 | 2017-07-27 | ||
| PCT/US2018/043908 WO2019023460A1 (en) | 2017-07-27 | 2018-07-26 | ANTIBODIES AGAINST M (H) DM2 / 4 AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF CANCER |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023069335A Division JP7629651B2 (ja) | 2017-07-27 | 2023-04-20 | Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020528936A JP2020528936A (ja) | 2020-10-01 |
| JP2020528936A5 true JP2020528936A5 (enExample) | 2021-09-02 |
Family
ID=63165539
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020527850A Withdrawn JP2020528936A (ja) | 2017-07-27 | 2018-07-26 | Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用 |
| JP2023069335A Active JP7629651B2 (ja) | 2017-07-27 | 2023-04-20 | Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用 |
| JP2025011548A Pending JP2025066140A (ja) | 2017-07-27 | 2025-01-27 | Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023069335A Active JP7629651B2 (ja) | 2017-07-27 | 2023-04-20 | Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用 |
| JP2025011548A Pending JP2025066140A (ja) | 2017-07-27 | 2025-01-27 | Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20210032364A1 (enExample) |
| EP (1) | EP3658178A1 (enExample) |
| JP (3) | JP2020528936A (enExample) |
| CN (1) | CN111491661B (enExample) |
| AU (2) | AU2018306436A1 (enExample) |
| CA (1) | CA3071105A1 (enExample) |
| SG (1) | SG11202000634UA (enExample) |
| WO (1) | WO2019023460A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220098328A1 (en) * | 2017-07-27 | 2022-03-31 | Nomocan Pharmaceuticals Llc | Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer |
| CA3071105A1 (en) | 2017-07-27 | 2019-01-31 | Nomocan Pharmaceuticals Llc | Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer |
| AU2019427766A1 (en) * | 2019-01-30 | 2021-09-16 | Nomocan Pharmaceuticals Llc | Antibodies to M(H)DM2/4 and their use in diagnosing and treating cancer |
| CA3130400A1 (en) * | 2019-02-20 | 2020-08-27 | Oncolyze, Inc. | Hdm2 antibody for use in treating cancer |
| CN116082500B (zh) * | 2022-12-09 | 2023-08-22 | 珠海重链生物科技有限公司 | 抗SARS-CoV-2抗体nCoV1和nCoV2及其应用 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| CN118497136A (zh) * | 2024-06-06 | 2024-08-16 | 华中农业大学 | 一种高亲和力鼠抗乌鳢IgM单克隆抗体、杂交瘤细胞株及应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5411860A (en) | 1992-04-07 | 1995-05-02 | The Johns Hopkins University | Amplification of human MDM2 gene in human tumors |
| DE4345249C2 (de) | 1993-11-19 | 1997-12-11 | Deutsches Krebsforsch | hdm-2-Fragmente mit Bindungsregionen für hdm-2-spezifische Antikörper |
| US5770377A (en) * | 1994-07-20 | 1998-06-23 | University Of Dundee | Interruption of binding of MDM2 and P53 protein and therapeutic application thereof |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| FR2738151B1 (fr) | 1995-09-04 | 1997-09-26 | Rhone Poulenc Rorer Sa | Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
| CN100387621C (zh) | 1997-04-14 | 2008-05-14 | 麦可麦脱股份公司 | 抗人抗原受体的新的生产方法及其用途 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| JP2005538706A (ja) | 2001-07-12 | 2005-12-22 | ジェファーソン フーテ， | スーパーヒト化抗体 |
| EP2224961A1 (en) | 2007-11-26 | 2010-09-08 | The Research Foundation of the State University of New York | Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells |
| US8822419B2 (en) | 2008-10-03 | 2014-09-02 | The Research Foundation Of State University Of New York | Membrane resident peptide in anti-cancer peptides causes tumor cell necrosis rather than apoptosis of cancer cells |
| CN102274186B (zh) * | 2010-06-11 | 2014-04-02 | 复旦大学 | 一种用于抗癌的镜像多肽脂质纳米制剂 |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| US9283272B2 (en) * | 2012-03-30 | 2016-03-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Targeting intracellular target-binding determinants with intracellular antibodies |
| WO2013143026A1 (en) * | 2012-03-31 | 2013-10-03 | Abmart (Shanghai) Co., Ltd | Peptide and antibody libraries and uses thereof |
| EP3662903A3 (en) | 2014-10-03 | 2020-10-14 | Novartis AG | Combination therapies |
| US9765117B2 (en) | 2015-08-24 | 2017-09-19 | Romek Figa | Peptides for treating cancer |
| CA3071105A1 (en) | 2017-07-27 | 2019-01-31 | Nomocan Pharmaceuticals Llc | Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer |
| AU2019427766A1 (en) | 2019-01-30 | 2021-09-16 | Nomocan Pharmaceuticals Llc | Antibodies to M(H)DM2/4 and their use in diagnosing and treating cancer |
-
2018
- 2018-07-26 CA CA3071105A patent/CA3071105A1/en active Pending
- 2018-07-26 JP JP2020527850A patent/JP2020528936A/ja not_active Withdrawn
- 2018-07-26 EP EP18752986.2A patent/EP3658178A1/en active Pending
- 2018-07-26 US US16/634,022 patent/US20210032364A1/en not_active Abandoned
- 2018-07-26 WO PCT/US2018/043908 patent/WO2019023460A1/en not_active Ceased
- 2018-07-26 SG SG11202000634UA patent/SG11202000634UA/en unknown
- 2018-07-26 AU AU2018306436A patent/AU2018306436A1/en not_active Abandoned
- 2018-07-26 CN CN201880062611.5A patent/CN111491661B/zh active Active
-
2021
- 2021-05-24 US US17/328,597 patent/US11407840B2/en active Active
-
2022
- 2022-07-25 US US17/814,596 patent/US20230295341A1/en not_active Abandoned
-
2023
- 2023-04-20 JP JP2023069335A patent/JP7629651B2/ja active Active
-
2025
- 2025-01-27 JP JP2025011548A patent/JP2025066140A/ja active Pending
- 2025-07-18 AU AU2025205612A patent/AU2025205612A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020528936A5 (enExample) | ||
| JP2023089245A5 (enExample) | ||
| JP2020501531A5 (enExample) | ||
| RU2019116624A (ru) | Новые анти_cd137 антитела и их применение | |
| JP2019536470A5 (enExample) | ||
| RU2019138067A (ru) | Биспецифическое антитело против ox40 и ctla-4 | |
| JP2018532383A5 (enExample) | ||
| CN110799543A (zh) | 肝细胞癌的免疫治疗 | |
| US20210040213A1 (en) | Immunomonotherapy for urothelial carcinoma | |
| JP2023037000A5 (enExample) | ||
| CN113574069A (zh) | 抗pd-l1抗体及其用途 | |
| US20240409632A1 (en) | Humanized antibodies against nectin-2 and drug conjugates thereof | |
| US12202899B2 (en) | Anti-human PD-L1 antibodies and their uses | |
| IL321677A (en) | Anti-PDL1 antibodies, multispecific antibodies, and methods of use | |
| JPWO2020081928A5 (enExample) | ||
| KR20240038769A (ko) | 항-ilt3 항체를 사용하여 급성 골수성 백혈병을 치료하는 방법 | |
| JPWO2021068841A5 (enExample) | ||
| JPWO2021092380A5 (enExample) | ||
| WO2024047654A1 (en) | Drug conjugates of humanized anti pvr antibodies | |
| WO2024062476A1 (en) | Humanized antibodies against nectin-4 and drug conjugates thereof | |
| JPWO2022263632A5 (enExample) | ||
| JPWO2020118295A5 (enExample) | ||
| RU2024119982A (ru) | Антитела к ox40, полиспецифические антитела и способы их применения | |
| RU2025100071A (ru) | Антитела против siglec15 и их применения | |
| RU2022119960A (ru) | Моноклональные антитела к tim-3 человека |